Global Viscosupplementation Market Size Was Worth USD 4.6 Billion in 2020 and Is Projected to Grow to USD 9.33 Billion by 2028

Visco-Supplementation: Introduction

Viscosupplementation involves injecting Hyaluronate (a viscous fluid) inside the joint. Viscosupplementation cannot treat osteoarthritis in the knee as there are no treatments for the condition. There is a belief that Hyaluronate can increase synovial fluid lubrication, reduce knee osteoarthritis pain, enhance mobility, and increase the amount of activity. Viscosupplementation usually occurs following all other treatments that are not able to alleviate discomfort. It is recommended to inject three to five times needed, spread out by a week. The injections are not able to solve all cases.

A lot of people suffer from some pain relief during the three to five-week course of injections. However, some experience delayed relief from pain. Most patients experience relief from pain between 8 and 12 weeks after the beginning of treatment. The time frame for pain relief differs, and some have seen improvements that last longer than six months following the injections. The most frequent adverse reactions to injections are a short-term discomfort around the injection site as well as heat, edema as well as redness and rash and bruising and irritation around the joint, as well as fluid accumulation in the injection knee. These reactions are usually mild and are short-lived. Bleeding and inflammation are other unexpected side effects that can result from injecting steroids.

The Global Visco-Supplementation Market Size And Forecast: 

Viscosupplementation market size was USD 4.6 billion in the year 2020, and it is predicted to reach USD 9.33 Billion by 2028. This will grow at an annual rate of 9.29 percent from 2021 to 2028.

The increasing prevalence worldwide of knee arthritis, rising desire for minimally-invasive procedures, and the growing aging population are just a few of the factors that may make it more profitable for the viscosupplementation over the projected time. This Global Viscosupplementation market report offers an in-depth analysis of the market. It provides an in-depth analysis of the most important segments and drivers, trends as well as restraints and the competitive landscape, as well as elements that play an important role on the scene.

The Global Visco-Supplementation Market Overview:

The increasing popularity of single injection treatment for osteoarthritis is predicted to drive market growth during the coming years. Other major causes of osteoporosis and osteoarthritis in the population include the growing acceptance of a sedentary lifestyle, smoking, as well as a changing habit of living. Very prevalent ailments among seniors are knee osteoarthritis. The rising incidence of cardiovascular diseases such as depression and renal failure, obesity, gastrointestinal bleeding, and hypertension is expected to boost the demand for treatment with viscosupplement and boost sales over the forecast period.

The market is predicted to grow due to the rising demand for non-surgical treatments for osteoarthritis as well an increase in the preference towards minimally invasive therapies, which result in less pain and quicker recovery. This market will also be affected by an increase in the need for permanent surgical procedures in lieu of long-term treatment and increasing demand for surgical procedures and technological advancements. Additionally, the advancements in technology in medical devices offer lucrative opportunities for competitors in the projected time. However, the high price of the hyaluronic acid treatment will likely hinder the growth of the market. The inefficiency and safety of the product are likely to hinder the Viscosupplementation Market during the forecast time.

Key Market Trends:

Ambulatory Surgical Centers show an enormous opportunity in the global Viscosupplementation Market.

The ambulatory surgery center is an establishment, which is located inside or separate from a hospital, which provides, under the direction of a licensed doctor, the diagnosis, or treatment or both, to patients who require medical, surgical, or mental health care.

Asia-Pacific is predicted to witness a high growth rate in the global Viscosupplementation Market.

This Asia-Pacific market is expected to grow rapidly over the forecast period due to the increasing cost of healthcare. Furthermore, the cost-effectiveness of production in China, as well as India, has led to a growth of production facilities, which has attracted biotech and pharmaceutical giants in the Asia-Pacific region from all over the globe.

The Key Market Segmentation of the Global Visco-Supplementation Market: 

This Research Report Categorized The Global Visco-Supplementation Market Based on Types, Application, End-User, and Geographical Landscape.

Visco-Supplementation Market Segmentation By Product Type:

Single Injection Viscosupplementation

Three Injection Viscosupplementation

Five Injection Viscosupplementation

Visco-Supplementation Market Segmentation By Source:

Animal

Non-animal

Visco-Supplementation Market Segmentation By Application:

Knee Osteoarthritis

Hip Osteoarthritis

Shoulder Osteoarthritis

Others

Visco-Supplementation Market Segmentation By End-User:

Hospitals

Orthopedic Clinics/ Ambulatory Surgical Centers

Retail Pharmacies

Online Sales

Visco-Supplementation Market Segmentation By Geographical Landscape:

North America

Europe

Asia Pacific

South America

Middle East and Africa

Major Key Players in the Global Visco-Supplementation Market Are:

• Sanofi, Anika Therapeutics, Inc., 
• Anika Therapeutics, Inc.
• Seikagaku Corp., 
• Zimmer Biomet, Smith & Nephew PLC, 
• Smith & Nephew PLC
• Ferring Pharmaceuticals B.V., 
• Lifecore Biomedical, 
• LG Life Sciences Ltd., 
• Fidia Farmaceutici S.p.A, 
• Hoffmann-La Roche Ltd.

The Global Visco-Supplementation Market Report Highlights:

In August 2021, the company Seikagaku Corporation had launched the HyLink, which is an intra-articular single injection for viscosupplement. It is used for the treatment of knee osteoarthritis in Taiwan.  

In May 2021, Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation had launched JOYCLU 30mg intra-articular injection, which is an agent for improving joint function. In March 2021, Japan has given manufacturing and marketing approval to the Seikagaku Corporation.